Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Olema Pharmaceuticals Inc OLMA

Healthcare Biotechnology
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an... see more

Recent & Breaking News (NDAQ:OLMA)

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

GlobeNewswire April 8, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 2, 2024

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 11, 2024

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

GlobeNewswire March 6, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 4, 2024

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire February 6, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2024

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

GlobeNewswire January 8, 2024

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

GlobeNewswire December 5, 2023

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2023

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswire November 28, 2023

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2023

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 2, 2023

Olema Oncology to Participate in Upcoming Investor Conferences in November

GlobeNewswire November 1, 2023

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

GlobeNewswire October 22, 2023

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

GlobeNewswire October 17, 2023

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

GlobeNewswire October 16, 2023

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

GlobeNewswire October 12, 2023

Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

GlobeNewswire October 10, 2023